QurCan Therapeutics (formerly Nanology Labs Inc) is a biotech company, developing next generation nanomedicine for treatment of hard-to treat, hard-to-reach diseases. QurCan Therapeutics' drug delivery platform technology enables active and targeted delivery of therapeutic compounds, including mRNAs and siRNAs to various solid tumor tissues, including those in the brain. QurCan's lead candidate, T-MX, is a first-in-class nanoparticle agent which can turn cold tumors hot via overcoming hypoxia in solid tumors.